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Abstract
Background: Autoimmune thyroid disease (AITD) comprises diseases including Hashimoto’s thyroiditis and Graves’ disease,
both characterized by reactivity to autoantigens causing, respectively, inflammatory destruction and autoimmune
stimulation of the thyroid-stimulating hormone receptor. AITD is the most common thyroid disease and the leading form of
autoimmune disease in women. Cytokines are key regulators of the immune and inflammatory responses; therefore, genetic
variants at cytokine-encoding genes are potential risk factors for AITD.
Methods: Polymorphisms in the IL6-174 G/C (rs1800795), TNFA-308 G/A (rs1800629), IL1B-511 C/T (rs16944), and IFNGR1-56
T/C (rs2234711) genes were assessed in a case-control study comprising 420 Hashimoto’s thyroiditis patients, 111 Graves’
disease patients and 735 unrelated controls from Portugal. Genetic variants were discriminated by real-time PCR using
TaqMan SNP genotyping assays.
Results: A significant association was found between the allele A in TNFA-308 G/A and Hashimoto’s thyroiditis, both in the
dominant (OR = 1.82, CI = 1.37–2.43, p-value = 4.461025) and log-additive (OR = 1.64, CI = 1.28–2.10, p-value = 8.261025)
models. The allele C in IL6-174 G/C is also associated with Hashimoto’s thyroiditis, however, only retained significance after
multiple testing correction in the log-additive model (OR = 1.28, CI = 1.06–1.54, p-value = 8.961023). The group with Graves’
disease also registered a higher frequency of the allele A in TNFA-308 G/A compared with controls both in the dominant
(OR = 1.85, CI = 1.19–2.87, p-value = 7.061023) and log-additive (OR = 1.69, CI = 1.17–2.44, p-value = 6.661023) models. The
risk for Hashimoto’s thyroiditis and Graves’ disease increases with the number of risk alleles (OR for two risk alleles is,
respectively, 2.27 and 2.59).
Conclusions: This study reports significant associations of genetic variants in TNFA and IL6 with the risk for AITD,
highlighting the relevance of polymorphisms in inflammation-related genes in the etiopathogenesis of AITD.
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Introduction
Autoimmune diseases, which affect 5 to 7% of the population
and are frequently responsible for severe disability, represent a
major cause of chronic illness and an important issue in general
healthcare [1]. Autoimmune thyroid diseases (AITD), including
Hashimoto’s thyroiditis (HT) and Graves’ disease (GD), are the
most common organ specific autoimmune disorders [2].
HT and GD stand for the major portion of clinical presentations
in a wide range of thyroid autoimmune conditions, which
culminate in thyroid dysfunction [3]. HT is a T cell-mediated
organ-specific autoimmune disease characterized by lymphocytic
infiltration that leads to thyroid cells loss, clinically expressed by
hypothyroidism [4]. In contrast, GD patients exhibit hyperthy-
roidism, which is due to excessive secretion of the thyroid hormone
induced by specific autoantibodies to the thyrotropin receptor
(TSHR) produced by TSHR-reactive B cells [5].
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The etiology of HT and GD involves common as well as unique
pathways. Both diseases carry thyroid reactive T cells that escape
the tolerance process and infiltrate the thyroid. Nevertheless,
distinct pathways lead thyroid-reactive T cells to either cause the
death of thyroid cells in HT or their stimulation in GD [6]. Thus,
there is presently awareness that the genetic susceptibility to HT
and GD involves both shared and unique genes [7].
Several factors, including genetic, hormonal, environmental,
and nutritional elements are involved in the initiation and/or
development of AITD, however the pathophysiologic changes
seen in AITD are mediated by inflammatory cytokines [3]. IL1b,
IL6 and TNFa cytokines, and IFNGR1 have proinflammatory
activity and represent important facilitators of the immunologic
process involved in HT and GD as components of the
autoimmune response [8–14]. Various cytokines and respective
genetic polymorphisms have been reported to be associated with
AITD, yet the results are inconsistent [8–12,15].
In the present work, a case-control study was performed to
assess if the risk to develop HT and GD is associated with the
promoter single nucleotide polymorphisms (SNPs) IL1B-511 C/T
(rs16944), TNFA-308 G/A (rs1800629), IL6-174 G/C
(rs1800795), and IFNGR1-56 T/C (rs2234711). This study
reports significant associations of promoter SNPs in TNFA and
IL6 with the risk for AITD and the combined effect of risk variants
for HT and GD development.
Materials and Methods
Study population
A total of 1266 Portuguese subjects were included in the study.
The patients group comprised 531 individuals (mean age
45.4616.0 years), 111 diagnosed with GD and 420 diagnosed
with HT. Patients were enrolled in the study from 2007 until 2013
and the number obtained reflects the relative incidence reported
for the two diseases (1GD/3.8HT) [16]. Patients’ clinicopatholog-
ical details are described in Table 1. The diagnosis of GD was
established on the basis of clinical findings, decreased serum
thyroid stimulating hormone (TSH) (,0.35 IU/mL), elevated
serum free thyroxine (FT4) (.1.48 ng/dL) and/or free triidothyr-
onine (FT3) (.3.71 pg/mL), positive serum antibodies to TSH-
receptor (TRAb) (.1.8 IU/L), and typical ultrasound signs
(hypoechogenicity and high perfusion). Diagnosis of HT was
obtained based on clinical findings, positive serum antibodies to
thyroid peroxidase (TPOAb) and/or thyroglobulin (TgAb) (ac-
cording to the method applied before or after March 2009 in the
Department of Clinical Pathology of Hospital S. Joa˜o), and
characteristic ultrasound signs (hypoechogenicity and non-homo-
geneous texture).
The control group included 735 unmatched samples obtained
from unrelated healthy blood donors (mean age 49.2616.8 years).
This group consisted of permanent residents in the catchment area
of Hospital of S. Joa˜o (Porto, Portugal), selected during the
assembling of the EpiPorto cohort [17]. Enrollment of participants
was performed under approval of Hospital of S. Joa˜o ethic
committee and included written informed consent for data and
DNA usage.
SNP genotyping
Patients and controls genomic DNA was isolated from blood
using standard proteinase K digestion with phenol/chloroform
extraction. SNPs IL1B-511 C/T (rs16944), TNFA-308 G/A
(rs1800629), IL6-174 G/C (rs1800795), and IFNGR1-56 T/C
(rs2234711) were genotyped using TaqMan Pre-Designed SNP
Genotyping Assays (Applied Biosystems, Carlsbad, USA). PCR
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amplification and allelic discrimination were performed according
to product specifications with the ABI 7500 Fast real-time PCR
system (Applied Biosystems, Carlsbad, USA). Optimization of
each TaqMan Assay was performed using controls of known
genotype selected through DNA sequencing. Cases and controls
were randomized during genotyping and 5% of the samples were
genotyped in duplicate to assess the genotyping error rate
(genotype concordance was 100%).
Statistical analysis
Genotype frequencies of all SNPs were obtained using SPSS 21
(IBM SPSS Statistics). Compliance of alleles at individual loci with
the Hardy-Weinberg equilibrium was measured at the level of the
control population using a x2 test (level of significance set to p-
value ,0.05) implemented in the SNPassoc 1.6-0 package in R
[18].
Comparison of genotype frequencies between groups defined by
status (HT and GD patients versus controls) was assessed by
unconditional logistic regression (level of significance set to p-value
,0.05) with the SNPassoc package implemented in R [18] and
included gender and age. Odds ratios (OR) with respective
confidence intervals (95% CI) were calculated considering the
genotypic, dominant and log-additive (per allele) models of
inheritance. The adjustment for multiple testing was performed
by the false discovery rate (FDR) method [19].
Results
In the control group, the frequencies of all SNPs did not deviate
significantly from those expected under Hardy-Weinberg equilib-
rium (p-value for IL1B-511, TNFA-308, IL6-174 and IFNGR1-
56 is, respectively, 0.059, 0.122, 0.491 and 0.347). The genotyping
success rate of all SNPs was 100% in the control and GD groups
and .99% in the HT group. The frequency of genotypes and
association parameters are summarized in Table 2.
The TNFA-308 A allele is significantly associated with HT risk
in the log-additive (OR=1.64, CI = 1.28–2.10, p-val-
ue=8.261025) and dominant models (OR=1.82, CI = 1.37–
2.43, p-value=4.461025). The frequency of the TNFA-308 A
allele was also higher in GD than in controls in both log-additive
and dominant models (OR=1.69, CI = 1.17–2.44, p-val-
ue=6.661023 and OR=1.85, CI = 1.19–2.87, p-val-
ue=7.061023, respectively).
A significant association was found between the IL6-174 allele
C and HT risk in the log-additive model (OR=1.28, CI = 1.06–
1.54, p-value=8.961023) but did not reach significance for the
dominant model (OR=1.31, CI = 1.01–1.71, p-value=0.0406)
after FDR correction (p-value ,0.0106).
Statistically significant differences were not observed in the
frequencies of genotypes and alleles of the IL1B-511 C/T, IL6-
174 C/G and IFNGR1-56 T/C polymorphisms between GD
patients and controls, and the IL1B-511 C/T and IFNGR1-56
C/T polymorphisms between HT patients and controls.
The joint effect of genetic polymorphisms was assessed
considering the high-risk genotypes TNFA A carrier and IL6 C
carrier (Table 3). The reference group contains no high-risk
genotypes, group 1 contains individuals with one of the high-risk
genotypes and group 2 contains individuals with two of the high-
risk genotypes. Individuals carrying two high-risk genotypes
present an increased risk for GD [OR (CI) = 2.59 (1.46–4.59), p-
value=1.261023] and for HT [OR (CI) = 2.27 (1.53–3.38), p-
value=5.461025].
Discussion
Our results report significant associations of genetic variants in
TNFA and IL6 with HT, and in TNFA with GD. The risk odds
were increased whenever an individual presented more than one
high-risk genotype. Genetic variants in proinflammatory cytokine
genes can have the potential to alter the regulation of the
transcript production or function. Considering the role of
proinflammatory cytokines in the pathogenesis of the autoimmune
response involved in GD and HT, a change in the function or the
quantity of a particular cytokine may lead to the initiation or
perpetuation of the inflammatory process. The importance of the
IL1b, TNFa, IL6, and IFNGR1 in the immunological response is
well established in the literature. Thus, SNPs in these cytokines
and receptor may have a role in the susceptibility to HT and GD
in which the immune response is a major feature.
TNFa plays an important role in the initiation of an adaptive
immune response [3]. TNFa is produced by monocytes, T cells,
natural killer cells, and mast cells. It is involved in the up-
regulation of the HLA class I, activation of phagocytes, induction
of IL1, IL6, and TNFa itself and, synergistically with IFNc,
enhancement of the HLA class II expression [11,20–22]. TNFa
mRNA is found in thyroid tissue from patients with GD and HT
in higher levels than in healthy subjects [23]. Our study reports a
statistically significant association between the TNFA-308 allele A
both with HT and GD. This is in agreement with previous studies
for GD [11,14,15,24–28] but not for HT [10,25,28]. It has been
observed that the TNFA-308 A allele is associated with a higher
level of the TNFA transcript, justified by the greater potency of the
promoter region to activate the transcription [29,30], which
suggests that the TNFA-308 A allele may have a role in the
pathogenesis of the AITD. Nevertheless, conflicting data were
reported concerning the genotypic and allelic frequencies of the
TNFA-308 G/A polymorphism in GD and HT
[9,10,25,28,31,32]. In fact, a meta-analysis of TNFA polymor-
phisms in GD reported an association of the TNFA-308 SNP in
Caucasians but not in Asians [33]. The TNFA gene is located in
the HLA class III domain of the major histocompatibility complex
(MHC) [34]. There are studies showing the genetic contribution of
the HLA regions for AITD susceptibility [35–38]. The HLA are
regions of strong linkage disequilibrium, thus it cannot be ruled
out that the association of TNFA variants with HT and GD might
not be due to polymorphisms within TNFA itself, but rather to
variation in a linked gene [25,28].
Polymorphisms in the IL6 promoter region have been
implicated in susceptibility to carotid atherosclerosis [39], multiple
myeloma [40], and juvenile chronic arthritis [41]. IL6 is mainly
produced by mononuclear phagocytes, under stimulation of IL1,
TNF or lipopolysaccharide. IL6, a Th2 cytokine, has been
connected with the modulation of thyroid cells function, and its
expression in thyrocytes correlated positively with the degree of
lymphocyte infiltration in HT [42,43]. Furthermore, IL6 plays a
major role in B cell differentiation and T cell proliferation, and the
deregulated production of IL6 and its receptor was related with
the pathogenesis of autoimmune diseases by inhibition of
autoreactive T cell apoptosis [44]. Our study reports an
association of the C allele in IL6-174 with the risk to develop
HT but not GD. This result is consistent with the lack of
association with GD in a Polish [8] and Taiwanese populations
[11]. In contrast, two other studies in an Iranian [15] and Turkish
[27] populations reported association of the IL6-174 SNP with
GD, albeit in the latter the association was on the threshold of
significance. To the best of our knowledge, there are no reports
implying the IL6-174 G/C polymorphism in HT susceptibility.
Genetic Risk Factors of Autoimmune Thyroid Disease
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Current data suggest that the C allele at the 2174 position is
responsible for lower expression of IL6, leading to lower IL6 serum
levels [45,46]. Other studies have demonstrated that patients with
HT have higher serum levels of IL6, inversely correlated with the
thyroid function [45,47,48]. Nevertheless, it has been reported that
the expression of IL6 occurs in a greater proportion of GD patients
than in HT patients, which may correlate with the different
lymphoid aggregate in the two AITD [43]. There is no evidence
that the IL6-174 G/C polymorphism is a causal variant for HT,
but our results may contribute to clarify some differences in the
pathogenesis of HT and GD.
Polymorphisms in the IL1 gene have been associated with other
autoimmune diseases such as rheumatoid arthritis [49], inflam-
matory bowel disease [50], and systemic lupus erythematosus [51].
IL1b has pleiotropic effects, can alter cytokine production, cell
signaling and migration, [52]. Several studies have reported
conflicting results regarding the possible role of IL1B-511 C/T
polymorphism in AITD. The TT genotype has been described as
a protective variant for GD [12,53,54], however, other studies did
not report any association between this polymorphism and GD or
HT [10,55,56]. In the present study, we also did not observe a
significant association between the IL1B-511 C/T polymorphism
and GD or HT. In agreement with our results, a recent meta-
analysis has reported that the IL1B-511 SNP is associated with
GD in Asians but not in Caucasians [57].
IFNGR1 encodes a class II cytokine receptor which is
ubiquitously expressed in nucleated cells and is the receptor for
IFNc, one of the most important Th1-related cytokines [58].
Several functions have been attributed to IFNc, such as the
enhancement of the expression of the HLA class I, class II and
some adhesion molecules on thyrocytes, including intercellular
adhesion molecule 1 (ICAM1) and lymphocyte function-associated
antigen 3 (LFA3) [15]. Previous studies have proposed a possible
association between polymorphisms in IFNc encoding genes and
the autoimmune response in GD [15,59]. Furthermore, a recent
study demonstrated that IFNcR knockout mice remained
thyroiditis resistant even after Treg-depletion [60]. In our study,
there was no association between the IFNGR1-56 T/C polymor-
phism and both HT and GD.
The association results obtained after TNFA and IL6 genotypes
combination reveal a risk increase for individuals harboring more
than one high-risk allele/genotype for both HT and GD. These
results are compatible with the individual effect of each variant
and point to a cumulative effect in the susceptibility for the disease.
However, larger studies are necessary to verify these observations
since, due to limited statistical power of the GD cohorts especially
after genotype combination, one should be cautious when
interpreting the results.
It is assumed that multiple factors interfere in the susceptibility
and initiation of AITD while others are responsible for the
perpetuation of the autoimmune process. Our study contributes to
the understanding of individual susceptibility to AITD when
carrier of risk alleles in certain cytokine-encoding genes (TNFA
and IL6), highlighting the relevance of polymorphisms in
inflammation-related genes as molecular markers for AITD.
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